Acolbifene

Acolbifene (INN) (developmental code names EM-652, SCH-57068) is a nonsteroidal selective estrogen receptor modulator (SERM) which, as of 2015, is in phase III clinical trials for the treatment of breast cancer.[1][2]

Acolbifene
Clinical data
Other namesEM-652; SCH-57068
Drug classSelective estrogen receptor modulator
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC29H31NO4
Molar mass457.570 g·mol−1
3D model (JSmol)

See also

References

  1. Gauthier S, Cloutier J, Dory YL, Favre A, Mailhot J, Ouellet C, et al. (April 2005). "Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution". Journal of Enzyme Inhibition and Medicinal Chemistry. 20 (2): 165–77. doi:10.1080/14756360500043448. PMID 15968821.
  2. "Acolbifene - Endoceutics". Adis Insight. Springer Nature Switzerland AG.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.